Kodiak Sciences is trading at $90.04, down -4.02%, with biotech-sector weakness a possible contributor.
- No clear company-specific announcement or event on October 6 explains the decline. The broader market is higher, while the supplied session context shows XBI down 2.50%.
- Recent coverage points to consolidation after the sharp rally sparked by positive Phase 3 DAYBREAK results; that earlier news is not a fresh catalyst. No volume information is available in the provided price context.